Publications
Learn about the research supporting our preclinical and clinical development programs.
Publications
August 18, 2020 An Assay for Periplasm Entry Advances the Development of Chimeric Peptide Antibiotics
ACS Infectious Diseases
May 12, 2020 MMAE delivery using the Bicycle toxin conjugate BT5528
Molecular Cancer Therapeutics
March 30, 2020 Identification and Optimization of EphA2-Selective Bicycles for Delivery of Cytotoxic Payloads
Journal of Medicinal Chemistry
February 15, 2019 Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors
AACR Journals
June 6, 2018 Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics
ADMET
March 8, 2018 Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema
Journal of Medicinal Chemistry
July 1, 2012 Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases
ChemMedChem
May 31, 2009 Phage-encoded combinatorial chemical libraries based on bicyclic peptides
Nature Chem Bio
Presentations
SITC
AACR Tumor Immunology & Immunotherapy
October 19, 2020
BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism
October 19, 2020
Development of CD137 (4-1BB) receptor occupancy assay using fluorescently labeled Bicycles®
ESMO
September 17, 2020
BT8009-100 Phase I/II Study of the Safety, Pharmacokinetics, & Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies
AACR
June 22, 2020
A novel fully synthetic dual targeted EphA2/CD137 Bicycle® peptide induces tumor localized CD137 agonist
June 22, 2020
BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonist
ASCO
2019
2018
